KR20220045030A - 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도 - Google Patents

다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도 Download PDF

Info

Publication number
KR20220045030A
KR20220045030A KR1020227008406A KR20227008406A KR20220045030A KR 20220045030 A KR20220045030 A KR 20220045030A KR 1020227008406 A KR1020227008406 A KR 1020227008406A KR 20227008406 A KR20227008406 A KR 20227008406A KR 20220045030 A KR20220045030 A KR 20220045030A
Authority
KR
South Korea
Prior art keywords
seq
ser
thr
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227008406A
Other languages
English (en)
Korean (ko)
Inventor
마날 아머리
앵거스 싱클레어
브루스 키트
Original Assignee
아이쥐엠 바이오사이언스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이쥐엠 바이오사이언스 인코포레이티드 filed Critical 아이쥐엠 바이오사이언스 인코포레이티드
Publication of KR20220045030A publication Critical patent/KR20220045030A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227008406A 2019-08-17 2020-08-14 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도 Ceased KR20220045030A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962888475P 2019-08-17 2019-08-17
US62/888,475 2019-08-17
US201962888702P 2019-08-19 2019-08-19
US62/888,702 2019-08-19
PCT/US2020/046335 WO2021034646A1 (en) 2019-08-17 2020-08-14 Multimeric bispecific anti-cd123 binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
KR20220045030A true KR20220045030A (ko) 2022-04-12

Family

ID=74659605

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227008406A Ceased KR20220045030A (ko) 2019-08-17 2020-08-14 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도

Country Status (10)

Country Link
US (1) US20220289856A1 (cg-RX-API-DMAC7.html)
EP (1) EP4013796A4 (cg-RX-API-DMAC7.html)
JP (1) JP7585305B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220045030A (cg-RX-API-DMAC7.html)
CN (1) CN114341179B (cg-RX-API-DMAC7.html)
AU (1) AU2020334882A1 (cg-RX-API-DMAC7.html)
CA (1) CA3147767A1 (cg-RX-API-DMAC7.html)
IL (1) IL289964A (cg-RX-API-DMAC7.html)
MX (1) MX2022002024A (cg-RX-API-DMAC7.html)
WO (1) WO2021034646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
KR20220035369A (ko) 2019-06-07 2022-03-22 아디맵 엘엘씨 고 친화도 항-cd3 항체, 및 이의 생성 및 사용 방법
EP4294829A4 (en) * 2021-02-17 2025-03-19 IGM Biosciences Inc. ANTI-CD123 BINDING MOLECULES AND THEIR USES
WO2022212191A1 (en) * 2021-04-01 2022-10-06 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
EP4380693A1 (en) * 2021-08-06 2024-06-12 Universität Basel Discernible cell surface protein variants for use in cell therapy
CA3231006A1 (en) * 2021-09-17 2023-03-23 Adimab, Llc Anti-cd3 antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045774A (en) * 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
SI3030575T1 (sl) * 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
EP4011910A1 (en) * 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
US10259887B2 (en) * 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AR103488A1 (es) * 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
ES2819870T3 (es) * 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
PT3355913T (pt) * 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
EP3464365A1 (en) 2016-06-01 2019-04-10 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
CA3055790A1 (en) * 2017-04-07 2018-10-11 Igm Biosciences, Inc. Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
CN110913895B (zh) * 2017-05-08 2024-04-02 阿迪马布有限责任公司 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法
CN108409840B (zh) * 2017-05-18 2020-06-23 重庆精准生物技术有限公司 抗cd123单链抗体及其组合的嵌合抗原受体和应用
CN111787951B (zh) * 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变

Also Published As

Publication number Publication date
AU2020334882A1 (en) 2022-02-24
CA3147767A1 (en) 2021-02-25
WO2021034646A1 (en) 2021-02-25
JP7585305B2 (ja) 2024-11-18
JP2022545655A (ja) 2022-10-28
EP4013796A4 (en) 2023-08-02
EP4013796A1 (en) 2022-06-22
CN114341179A (zh) 2022-04-12
US20220289856A1 (en) 2022-09-15
IL289964A (en) 2022-03-01
MX2022002024A (es) 2022-03-11
BR112022002897A2 (pt) 2022-05-10
CN114341179B (zh) 2025-01-28

Similar Documents

Publication Publication Date Title
JP7585305B2 (ja) 多量体の二重特異性抗cd123結合分子及びその使用
KR102696143B1 (ko) 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
US20230203119A1 (en) Immunostimulatory multimeric binding molecules
US20220372142A1 (en) Multimeric antibodies with enhanced selectivity for cells with high target density
KR20230005228A (ko) Pd-1 효능제 다량체 결합 분자
US20240076392A1 (en) Anti-cd123 binding molecules and uses thereof
JP2021521275A (ja) Nk細胞結合抗体融合構築物
US20220306760A1 (en) Igm glycovariants
KR20240139079A (ko) 항-cd38 결합 분자 및 이의 용도
BR112022002897B1 (pt) Anticorpo multimérico e biespecífico e uso do mesmo para tratar leucemia mieloide aguda
CN116964081A (zh) 抗cd123结合分子及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601